Compare FPI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | DSGN |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.7M | 504.7M |
| IPO Year | 2014 | 2021 |
| Metric | FPI | DSGN |
|---|---|---|
| Price | $10.58 | $9.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 517.0K | 498.7K |
| Earning Date | 02-18-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 296.76 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $52,990,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.37 | $2.60 |
| 52 Week High | $12.87 | $10.31 |
| Indicator | FPI | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 69.99 | 51.98 |
| Support Level | $10.05 | $8.82 |
| Resistance Level | $9.73 | $10.01 |
| Average True Range (ATR) | 0.19 | 0.65 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 99.61 | 62.37 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.